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Table 1. Radiographic finding classification system 
Minor Findings 
1.1 Single fibrous streak/band/scar 
1.2 Bony islets 
2.1 Pleural capping with a smooth inferior border (<1cm thick at all points) 
2.2 Unilateral or bilateral costophrenic angle blunting (below the horizontal) 
2.3 Calcified nodule(s) in the hilum / mediastinum with no pulmonary granulomas  
Minor findings occasionally associated with tuberculosis infection 
3.1 Solitary Granuloma (< 1 cm and of any lobe) with an unremarkable hilum 
3.2 Solitary Granuloma (< 1 cm and of any lobe) with calcified / enlarged hilar lymph nodes 
3.3 Single / Multiple calcified pulmonary nodules / micronodules with distinct borders 
3.4 Calcified pleural lesions 
3.5 Costophrenic Angle blunting (either side above the horizontal)  
Major findings sometimes seen in active tuberculosis (or other conditions) 
4.0 
Notable apical pleural capping (rough or ragged inferior border and/or ≥ 1cm thick at 
any point)  
4.1 Apical fibronodular / fibrocalcific lesions or apical microcalcifications 
4.2 
Multiple / single pulmonary nodules / micronodules (noncalcified or poorly defined) 4.3 
Isolated hilar or mediastinal mass/lymphadenopathy (non-calcified) 
4.4 Single / multiple pulmonary nodules / masses ≥ 1 cm.” 
4.5 Non-calcified pleural fibrosis and / or effusion. 
4.6 Interstitial fibrosis/ parenchymal lung disease/ acute pulmonary disease 
4.7 Any cavitating lesion OR “fluffy” or “Soft” lesions felt likely to represent active TB  
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It was possible for individuals screened pre-entry to have multiple entries in the IOM 
database for several reasons, including: 1) clearance certificates are only valid for six 
months (or three months if migrants reported history of contact with a case of 
tuberculosis), and if a UK visa application was not processed during this time period 
then the applicant was required to undergo repeat screening with a duplicate record 
being created; 2) administrative errors leading to two records being created for one 
individual during the same screening application; 3) migrants undergoing a clearance 
screen after an initial positive screen for tuberculosis. The rules used to determine 
whether more than one entry for an individual was included in this analysis are detailed 
in supplementary appendix Table S2. 
Duplicates were analysed on the basis of whether they occurred less than 12 months 
apart or not. A period of 12 months was chosen a-priori as this was long enough to 
capture individuals found to have tuberculosis on their first screen, who were then 
undergoing repeat screening for visa clearance, but not too long a time period such that 
tuberculosis exposure and risk factors may have changed significantly for a majority of 
individuals.  
For duplicates occurring less than 12 months apart where the first screen was positive, 
the second screen has been undertaken for clearance purposes. This second screen is 
therefore treated as a continuation of the initial screening process taken for the purposes 
of clearance and was excluded as it is not a newly prevalent case, the primary outcome 
for this analysis. All duplicates occurring greater than 12 months apart were included as 
this is sufficient time for the exposure to tuberculosis in an individual to have changed.  
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Table 2. Rules for dealing with duplicate screens.  
    First screen TB result 
    Positive Negative 
L
as
t 
sc
re
en
 T
B
 r
es
u
lt
  
Positive Less than or equal to 12 months apart: 
1
st
 screen - Include 
2
nd
 screen - Exclude 
Greater than 12 months apart: 
Include all duplicates  
Include all  
Negative Less than or equal to 12 months apart: 
1
st
 screen - Include 
2
nd
 screen - Exclude 
Greater than 12 months apart: 
Include all duplicates 
Include all  
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Table 3. Data sources of variables, methods of assessment, details of subgroups 
Variable 
Data 
Source 
Methods of 
assessment Subgroups chosen for analysis  
Age IOM 
From visa 
application data 0-15; 16-44; 45-64; >65 
Sex IOM 
From visa 
application data Male; Female 
Close or 
household 
contact with 
a case of TB IOM 
Self report to 
panel physician 
screening 
applicant Yes; No. Where null assumed to be No 
Visa Type IOM 
From visa 
application data 
 Student - All students who receive (or do not 
received) a scholarship; 
 Settlement and Dependent - Those applicants who 
are settling permanently in the UK, as well as 
spouses, partners/civil partners, fiancées, fiancés, 
proposed  partners/civil partners, children, other 
dependant relatives; 
 Work - This type of visa is intended for work 
related visas, including work requiring a permit, 
and the highly skilled migrant program. This 
category EXCLUDES the working holiday maker 
category, which has been assigned a separate 
category (see below);   
 Working Holiday Maker - Applicants going to the 
UK on the working holiday maker program;   
 Family Reunion - Type of settlement that allows the 
family members of a recognized refugee to join 
him/her in the UK;  
 Other - this category is used when the applicant’s 
visa category is not readily identified. 
 
CXR  IOM 
  
CXR 
classification 
chosen by panel 
physician after 
double reading by 
radiologist.  
 No abnormality, or abnormality classified in groups 
1, 2, and 3 in Table 1. 
 Compatible with TB – As detailed in Table 1 of 
appendix - major findings sometimes seen in active 
tuberculosis (or other conditions); or Minor findings 
occasionally associated with tuberculosis infection 
and that panel physician determines on basis of 
clinical history and examination require sputum 
sampling to rule out TB disease.  
 Abnormality not TB – Finding on CXR that is not 
normal, but does not consistent with TB 
 
Prevalence 
of TB in 
country of 
migration WHO 
WHO modelling 
data taken from 
http://www.who
.int/tb/publicatio
ns/global_report
/en/  40-149; 150-349; 350+ 
Year of 
examination  IOM 
Based on IOM 
data and date of 
screening 
recorded by panel 
physician.  
2005 ;2006; 2007; 2008; 2009; 2010; 2011; 2012; 2013 
 
Country of IOM From screening Burkina Faso;  Bangladesh; Cambodia; Cote D'Ivoire; 
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screening location recorded 
in IOM dataset 
Eritrea; Ghana; Kenya; Laos; Niger; Pakistan; Sudan; 
Somalia; Togo; Tanzania; Thailand 
 
Sputum 
culture 
testing IOM 
From IOM dataset 
based on dates of 
the roll out of 
culture testing 
according to UK 
technical 
instructions.   Yes; No 
 
 
Updated systematic review and meta-analysis 
For this analysis we updated our our previous systematic review and meta-analysis.
1
 We 
identified new articles published since the original review up until 19
th
 November 2015. 
The updated review used the original search terms, summarised as: the populations of 
interest (migrants, refugees, asylum seekers, new entrants, undocumented migrants), the 
intervention (pre-entry screening), and standard terms for tuberculosis. The updated 
search was conducted in Medline and Embase. Experimental, observational and 
systematic reviews were included. Only studies reporting culture positive results by 
country were included in this updated review and meta-analysis. 
Fixed effects models with Freeman-Tukey transformation of data were used to estimate 
the summary prevalence of pre-entry screening across studies and subgroups where 
appropriate.
2,3
 The I-squared transformation was used to describe the proportion of total 
variation in study estimates that is due to heterogeneity.
4
 Where overlapping data on an 
individual screening programme were identified, the publication with the largest amount 
of data (by time period or number of individuals screened) was included in this review.  
Subgroup analysis was carried out for the primary outcomes to examine the impact of 
prevalence in the country of origin. Consistent with our previous review, we chose to 
use the following groups: 20-49; 50–149; 150–249; 250–349, and ≥350/100 000 cases 
per 100,000 population.  
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Table 4. Baseline characteristics of all applicants screened (regardless of whether 
culture testing of sputum was performed) for tuberculosis and prevalence of 
primary and secondary outcomes (2005-2013). 
  N (%) 
Prevalence per 100,000 
 
 
Bacteriologically 
confirmed 
(95%CIs) 
Culture positive 
(95%CIs) 
Smear positive 
(95%CIs) 
          
All 692232 (100.0%) 75 (69, 82) 58 (52, 63) 52 (47, 58) 
          
Age group         
0-15 25555 (3.7%) 27 (13, 57) 27 (13, 57) 8 (2, 31) 
16-44 647178 (93.5%) 75 (69, 82) 57 (52, 64) 50 (45, 56) 
45-64 15829 (2.3%) 107 (67, 173) 76 (43, 133) 152 (102, 226) 
>65 3670 (0.5%) 300 (166, 540) 218 (109, 435) 245 (128, 471) 
          
Sex         
Female 242592 (35.0%) 94 (83, 108) 75 (64, 86) 73 (63, 85) 
Male 449640 (65.0%) 65 (58, 73) 48 (42, 55) 40 (35, 47) 
          
Close or household contact with a case of 
TB       
No 688296 (99.8%) 73 (67, 80) 56 (50, 62) 50 (45, 56) 
Yes 1604 (0.2%) 1185 (757, 1853) 935 (565, 1548) 686 (380, 1236) 
          
Visa Type         
Student 390803 (56.5%) 70 (62, 79) 55 (48, 63) 48 (41, 55) 
Settlement and 
Dependent 233015 (33.7%) 87 (76, 100) 69 (59, 81) 56 (47, 67) 
Work 26823 (3.9%) 78 (51, 120) 37 (20, 69) 0 (0, 0) 
Working Holiday 
Maker 21043 (3.0%) 52 (29, 94) 29 (13, 63) 29 (13, 63) 
Family Reunion 5639 (0.8%) 124 (59, 260) 35 (9, 142) 0 (0, 0) 
Other 14909 (2.2%) 40 (18, 90) 34 (14, 81) 34 (14, 81) 
          
CXR         
No abnormality 652313 (94.2%) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
TB suspected 28552 (4.1%) 1821 (1672, 1983) 1394 (1264, 1537) 1229 (1108, 1364) 
Abnormality not 
TB 11367 (1.6%) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
          
WHO prevalence of TB in country of 
migration       
40-149 39060 (5.6%) 15 (7, 34) 5 (1, 20) 13 (5, 31) 
150-349 99114 (14.3%) 181 (156, 209) 153 (131, 180) 168 (145, 196) 
350+ 554058 (80.0%) 61 (55, 67) 44 (39, 50) 34 (29, 39) 
          
Year of 
examination         
2005 994 (0.1%) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
2006 31266 (4.5%) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
2007 97828 (14.1%) 52 (40, 69) 8 (4, 16) 0 (0, 0) 
2008 109604 (15.8%) 67 (53, 84) 48 (37, 63) 0 (0, 0) 
2009 132816 (19.2%) 83 (69, 100) 64 (52, 79) 63 (51, 78) 
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2010 109356 (15.8%) 68 (54, 85) 56 (43, 72) 47 (35, 61) 
2011 97455 (14.1%) 87 (71, 108) 82 (66, 102) 33 (23, 46) 
2012 62338 (9.0%) 106 (83, 135) 103 (80, 131) 59 (43, 82) 
2013 50575 (7.3%) 93 (70, 124) 93 (70, 124) 32 (19, 52) 
          
Country of 
screening         
Burkina Faso 117 (0.0%) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Bangladesh 180612 (26.1%) 80 (68, 94) 61 (51, 73) 44 (36, 55) 
Cambodia 741 (0.1%) 135 (19, 958) 135 (19, 958) 0 (0, 0) 
Cote D'Ivoire 1531 (0.2%) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Eritrea 238 (0.0%) 420 (59, 2989) 0 (0, 0) 420 (59, 2989) 
Ghana 38644 (5.6%) 16 (7, 35) 5 (1, 21) 13 (5, 31) 
Kenya 16868 (2.4%) 119 (77, 184) 77 (45, 133) 77 (45, 133) 
Laos 229 (0.0%) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Niger 82 (0.0%) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Pakistan 369194 (53.3%) 49 (42, 57) 35 (29, 42) 27 (22, 33) 
Sudan 7596 (1.1%) 26 (7, 105) 13 (2, 93) 0 (0, 0) 
Somalia 3282 (0.5%) 274 (143, 526) 122 (46, 324) 213 (102, 447) 
Togo 299 (0.0%) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Tanzania 10859 (1.6%) 55 (25, 123) 46 (19, 111) 37 (14, 98) 
Thailand 61940 (9.0%) 242 (206, 285) 215 (181, 255) 239 (203, 281) 
          
Sputum culture 
testing         
Yes 215777 (31.2%) 92 (84, 101) 83 (75, 92) 55 (49, 62) 
No 476455 (68.8%) 38 (31, 47) 0 (0, 0) 38 (31, 47) 
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Equation 1. Formula used for calculation of Population attributable fraction (PAF).
5
 
𝑷𝑨𝑭 =
𝒑 ∗ (𝑹𝒆𝒍𝒂𝒕𝒊𝒗𝒆 𝒓𝒊𝒔𝒌 − 𝟏)
𝒑 ∗ (𝑹𝒆𝒍𝒂𝒕𝒊𝒗𝒆 𝒓𝒊𝒔𝒌 − 𝟏) + 𝟏
 
p=proportion of the total population exposed to the risk factor. 
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Figure 1. Location of pre-entry screening sites globally (includes IOM and non-IOM 
sites).  
 Note: IOM pre-entry pilot scheme countries were Bangladesh, Burkina Faso, 
Cambodia, Cote D'Ivoire, Eritrea, Ghana, Kenya, Laos, Niger, Pakistan, Somalia, 
Sudan, Tanzania, Thailand, and Togo. Some additional countries after the pre-
entry pilot have been conducted directly with countries and without the 
involvement of IOM.  
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Figure 2.  Crude prevalence of bacteriological and culture confirmed TB diagnosed at 
pre-entry screening compared to 2010 WHO country prevalence estimates 
(2007-2013).  
 Note: Error bars on bacteriological and culture confirmed tuberculosis 
estimates are 95%confidence intervals.  Error bars on WHO 2010 
prevalence country estimates are highest and lowest prevalence estimate for 
each country between 2007 and 2013. Confidence intervals limited to a 
maximum of 1,000 per 100,000 population for convenience of plotting. 
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